BindwellYC W25 landing page report.
← Back to YC W25

Score over time

70605040302010AgPlenus 49 on Sep 22 (Live)Insilico Medicine 54 on Jun 16 (Wayback)Insilico Medicine 55 on Jun 27 (Wayback)Insilico Medicine 56 on Jul 15 (Wayback)Insilico Medicine 56 on Jul 26 (Wayback)Insilico Medicine 56 on Aug 10 (Wayback)Insilico Medicine 57 on Sep 9 (Wayback)Insilico Medicine 54 on Sep 22 (Live)Micropep Technologies 56 on Apr 13 (Wayback)Micropep Technologies 55 on May 15 (Wayback)Micropep Technologies 55 on Jun 9 (Wayback)Micropep Technologies 55 on Jul 9 (Wayback)Micropep Technologies 56 on Aug 7 (Wayback)Micropep Technologies 54 on Sep 10 (Wayback)Micropep Technologies 56 on Sep 20 (Live)Iambic Therapeutics 54 on Apr 27 (Wayback)Iambic Therapeutics 55 on May 10 (Wayback)Iambic Therapeutics 56 on May 21 (Wayback)Iambic Therapeutics 56 on Jun 7 (Wayback)Iambic Therapeutics 55 on Jul 11 (Wayback)Iambic Therapeutics 57 on Sep 4 (Wayback)Iambic Therapeutics 52 on Sep 20 (Live)Charm Therapeutics 52 on Apr 11 (Wayback)Charm Therapeutics 51 on May 15 (Wayback)Charm Therapeutics 23 on Jun 11 (Wayback)Charm Therapeutics 51 on Jul 24 (Wayback)Charm Therapeutics 52 on Aug 20 (Wayback)Charm Therapeutics 57 on Sep 22 (Live)Bindwell 62 on Apr 10 (Wayback)Bindwell 62 on Apr 20 (Wayback)Bindwell 63 on Jun 17 (Wayback)Bindwell 28 on Sep 22 (Live)Apr 10Apr 20Jun 17Sep 22
Past reportsShow past reportsHide past reports
  1. Sep 22, 202628LiveOverall −35 · CTA −43 · Value props −40Viewing
  2. Jun 17, 202663Overall +1 · Mobile web +8 · Trust −2View →
  3. Apr 20, 202662No score movementView →
  4. Apr 10, 202662First tracked report — strongest Trust 68, weakest Information hierarchy 58View →

CTA

15Poor

Copy, size, verb, cost-feel — does the primary CTA earn the click?

Micropep Technologies
REGISTER NOW!
Insilico Medicine
Discover
Charm Therapeutics
LEARN MORE ABOUT OUR INNOVATION
AgPlenus

Problems

  • no CTA anywhere in the fold
  • no nav or secondary link either
  • fold is logo + graphic only

Value props

18Poor

Title, subtitle, hero — do they sell the product's true value?

Bindwell’s headline vagueBindwell

Working

  • Clean, memorable brand presentation
  • Protein visual signals biotech domain

Could improve

  • No value claim anywhere in the fold
  • No subhead, proof, or numbers
  • Visual decorates, doesn't demonstrate

Trust

30Poor

Proof that the product is real, competent, and safe to try.

Insilico Medicine
Charm Therapeutics
AgPlenus
Trust read
BindwellNo visible trust signal identified.
AgPlenus"Our Innovation" list detailing the platform: "Scanning billions of compounds", "De novo design of small molecules"
Insilico MedicinePipeline table rows showing "Out-licensed to Exelixis" and "Out-licensed to Menarini" with Phase I–III progress bars and
Micropep TechnologiesNo visible trust signal identified.
Iambic TherapeuticsNo visible trust signal identified.
Charm TherapeuticsHeadline "Addressing resistance in AML with a best-in-class menin inhibitor" naming a specific target and indication

Information hierarchy

38Poor

Does the design help or inhibit what the page is trying to say?

Information hierarchy annotations on the desktop capture12
  1. Bindwell wordmark — Stands alone with no headline, subtitle, or CTA — the fold communicates a name and nothing else.
  2. Protein ribbon illustration — The visual anchor hints at biology but carries the entire message alone with no caption or claim to land it.

Mobile web

38Poor

The phone experience as a first-class citizen.

Mobile web annotations on the mobile capture12
  1. Bindwell wordmark — The only text in the fold — no value statement or CTA accompanies it, leaving visitors with nothing to act on.
  2. Protein visualization — Decorative graphic occupies the center of the fold without communicating what Bindwell does or linking anywhere.